Genetic polymorphisms and anti-tuberculosis drug-induced liver injury: an umbrella review of the evidence
International Journal of Clinical Pharmacy · 2025-06 · 47 (3) · 624-639
DOI: 10.1007/s11096-025-01880-9 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Clinical Pharmacy, online erschienen am 15.02.2025. Verfasst von Jingru Cheng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, 211166, People's Republic of China. Hauptthemen laut MEDLINE: Antitubercular Agents, Chemical and Drug Induced Liver Injury, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, Jiangsu University General project of Medical Education Collaborative Innovation Fund, Medical Research project of Jiangsu Provincial Health Commission.
Abstract (Originalsprache)
BACKGROUND: Anti-tuberculosis drug-induced liver injury (ATLI) is a significant adverse drug reaction with genetic susceptibility implications. AIM: This study aimed to integrate findings from systematic reviews and meta-analyses on genetic polymorphisms associated with ATLI risk, enhance evidence synthesis, and identify susceptibility gene polymorphisms linked to ATLI occurrence. METHOD: The protocol was registered in PROSPERO (CRD42024517311). Systematic searches of PubMed, EMBASE, Web of Science, and Cochrane Library databases were conducted to identify eligible studies from inception to February 21, 2024. Two authors independently reviewed eligibility, extracted data, and assessed quality. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate associations between genetic polymorphisms and ATLI susceptibility. RESULTS: A total of 25 meta-analyses were included, including 57 single nucleotide polymorphisms (SNPs) in 15 candidate genes. Significant associations were found for the glutathione S-transferase M1 (GSTM1) null genotype (OR = 1.43, 95% CI: 1.18-1.73, P < 0.001) and N-acetyltransferase 2 (NAT2) polymorphisms, including rs1799929 (dominant model, OR = 1.35, 95% CI: 1.12-1.63, P < 0.001), rs1799930 (dominant model, OR = 1.43, 95% CI: 1.23-1.66, P < 0.001), rs1799931 (dominant model, OR = 1.22, 95% CI: 1.02-1.46, P = 0.03), and the slow acetylator (SA) phenotype (OR = 2.91, 95% CI: 2.43-3.49, P < 0.001). No significant association was found between the CYP2E1 RsaI/PstI polymorphism (C1/C1 genotype) and ATLI risk (dominant model, OR = 0.79, 95% CI: 0.61-1.02, P = 0.08). CONCLUSION: This umbrella review confirms that the GSTM1 null genotype, NAT2 polymorphisms (rs1799929, rs1799930, rs1799931), and the slow acetylator phenotype are associated with increased ATLI risk. These findings provide a foundation for further research on genotype-guided approaches to mitigating ATLI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, 211166, People's Republic of China.
- Department of Prevention and Healthcare, Changzhou Xinbei District Sanjing People's Hospital, Changzhou, China.
- Department of Infectious Disease, The Jurong Hospital Affiliated to Jiangsu University, Jurong, China.
- Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, 211166, People's Republic of China. tomswen@njmu.edu.cn.
ORCID-Profile: Shaowen Tang
Förderung
- the National Natural Science Foundation of China
- Jiangsu University General project of Medical Education Collaborative Innovation Fund
- Medical Research project of Jiangsu Provincial Health Commission
Zitieren
APA
Cheng, J., Zhu, J., Chen, R., Zhang, M., Han, B., Zhu, M., He, Y., Yi, H., & Tang, S. (2025). Genetic polymorphisms and anti-tuberculosis drug-induced liver injury: an umbrella review of the evidence. International Journal of Clinical Pharmacy, 47(3), 624-639. https://doi.org/10.1007/s11096-025-01880-9
Vancouver
Cheng J, Zhu J, Chen R, Zhang M, Han B, Zhu M, et al. Genetic polymorphisms and anti-tuberculosis drug-induced liver injury: an umbrella review of the evidence. International Journal of Clinical Pharmacy. 2025;47(3):624-639. doi:10.1007/s11096-025-01880-9
BibTeX
@article{Cheng2025,
author = {Cheng, Jingru and Zhu, Jia and Chen, Ruina and Zhang, Meiling and Han, Bing and Zhu, Min and He, Yiwen and Yi, Honggang and Tang, Shaowen},
title = {Genetic polymorphisms and anti-tuberculosis drug-induced liver injury: an umbrella review of the evidence},
journal = {International Journal of Clinical Pharmacy},
year = {2025},
volume = {47},
number = {3},
pages = {624--639},
doi = {10.1007/s11096-025-01880-9}
}
EUVIMED